Jazz Pharmaceuticals plc (JAZZ)
Why Is Jazz (JAZZ) Up 1% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Jazz Pharmaceuticals plc (JAZZ) Presents at TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Transcript
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Jazz Pharmaceuticals plc (JAZZ) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
International Markets and Jazz (JAZZ): A Deep Dive for Investors
Examine the evolution of Jazz's (JAZZ) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Jazz Pharmaceuticals Q1 Review: The Oncology Pivot Is Real, And The Market Is Still Mispricing It
Jazz Pharmaceuticals remains a Strong Buy, with Q1 2026 results affirming robust growth and a successful pivot into oncology. JAZZ's oncology segment, led by Ziihera, Modeyso, and Zepzelca, is driving double-digit sales growth and diversifying away from legacy neuroscience revenues. Ziihera's Priority Review for HER2+ GEA and multiple late-stage trials position JAZZ for significant market expansion and $2B+ peak sales potential via a HER2+ 'pipeline-in-a-product.'
JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations
Jazz Pharmaceuticals tops Q1 estimates as revenues jump 19%, driven by strong Xywav, Epidiolex and oncology drug sales growth.
Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript
Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Top Estimates
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.34 per share, beating the Zacks Consensus Estimate of $4.67 per share. This compares to earnings of $1.68 per share a year ago.
